NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
1.620
+0.020 (1.25%)
Jul 31, 2026, 4:00 PM EDT - Market closed
NervGen Pharma Earnings Call Transcripts
Fiscal Year 2026
-
NVG-291, a peptide therapy for chronic cervical spinal cord injury, showed significant functional and quality-of-life improvements in the CONNECT trial, with a strong safety profile. The upcoming RESTORE phase III trial is designed for regulatory approval, targeting a large unmet need and leveraging a cost-efficient, scalable approach.